Publication | Closed Access
Phase II evaluation of hexamethylmelamine in advanced breast cancer: a Southwest Oncology Group study.
10
Citations
0
References
1979
Year
Breast OncologyCancer ManagementNinety-eight PatientsPharmacotherapyAdvanced Breast CancerOncologyMetronomic TherapyHex-alone GroupAnti-cancer AgentRadiation OncologyCancer ResearchDrug ToxicityRadiologyHealth SciencesPhase Ii EvaluationMetastatic Breast CancerCancer TreatmentPharmacologyBreast CancerMedicine
Ninety-eight patients with metastatic breast cancer, heavily pretreated with other agents, were entered in a phase II trial of hexamethylmelamine (HEX). Patients were randomized to receive HEX alone or combined with prophylactic pyridoxine. There was a 2% response rate in 89 partially or fully evaluable patients. Seven percent of these patients developed neurologic toxicity which occurred in the HEX-alone group only.